Request Demo

Last update 20 Dec 2025

REGN-5714

Last update 20 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-Bet v 1 Monoclonal Antibodies, REGN-5714

Target

Bet v 1

Action

inhibitors

Mechanism

Bet v 1 inhibitors(Bet v 1 Protein inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesEye Diseases+ [2]

Active Indication-

Inactive Indication

AnaphylaxisConjunctivitisRhinitis, Allergic, Seasonal

Originator Organization

Regeneron Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Regeneron Pharmaceuticals, Inc.

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Structure/Sequence

Sequence Code 2171CDR1-LCDR2-L

Sequence Code 2278CDR1-LCDR2-L

Sequence Code 10217CDR1-LCDR2-L

Sequence Code 17330CDR1-LCDR3-L

Sequence Code 29028CDR1-L

Sequence Code 38899CDR1-L

Sequence Code 43789VL

Sequence Code 159499CDR1-H

Sequence Code 1146474L

Sequence Code 9822999CDR2-H

Sequence Code 319240641VH

Sequence Code 319240642CDR2-H

Sequence Code 319240643CDR3-H

Sequence Code 319240644VL

Sequence Code 319240645CDR1-LCDR3-L

Sequence Code 319240656VH

Sequence Code 319240657CDR1-H

Sequence Code 319240658CDR3-H

Sequence Code 319240659VL

Sequence Code 319240660CDR1-L

Sequence Code 319240661CDR1-LCDR3-L

Sequence Code 319240705VH

Sequence Code 319240706CDR1-H

Sequence Code 319240707CDR2-H

Sequence Code 319240708CDR3-H

Sequence Code 319240716H

Sequence Code 319240717L

Sequence Code 319240720H

Sequence Code 319240721L

Sequence Code 319240722H

Clinical Trials associated with REGN-5714

NCT05430919

/ CompletedPhase 2

A Two-Part Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy of the Anti-Bet v 1 Monoclonal Antibodies to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen

Primary objective: To assess the efficacy of a single dose of the anti- Bet v 1 monoclonal antibodies (mAb(s ) in the reduction of allergic nasal symptoms during an out-of-season birch allergen environmental exposure unit (EEU) challenge in participants receiving REGN5713-5714-5715 versus placebo (Part A)

Start Date15 Aug 2022

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT04709575

/ CompletedPhase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis

The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

Start Date14 Jan 2021

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT03969849

/ CompletedPhase 1

A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Subjects

The primary objective of the study is to evaluate the safety and tolerability of REGN5713-5714-5715 in healthy adult participants.
The secondary objectives of the study are:
In Part A and Part B:
* To characterize the concentration time profile of single doses of REGN5713-5714-5715 in healthy adults
* To assess the immunogenicity of single dose of REGN5713-5714-5715.
In Part B:
* To assess the inhibition of allergic symptoms as measured by total nasal symptom score (TNSS) provoked by a birch allergen nasal allergen challenge (NAC) in birch-sensitized allergic subjects after a single subcutaneous (SC) dose of REGN5713-5714-5715
* To assess the skin test reactivity provoked by a skin prick test (SPT) with serial birch allergen titration after a single SC dose of REGN5713-5714-5715.

Start Date03 Jun 2019

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with REGN-5714

100 Translational Medicine associated with REGN-5714

100 Patents (Medical) associated with REGN-5714

100 Deals associated with REGN-5714

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	Phase 3	United States	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Conjunctivitis	Phase 3	Belgium	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Conjunctivitis	Phase 3	Canada	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Conjunctivitis	Phase 3	Denmark	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Conjunctivitis	Phase 3	Germany	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Rhinitis, Allergic, Seasonal	Phase 3	United States	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Rhinitis, Allergic, Seasonal	Phase 3	Belgium	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Rhinitis, Allergic, Seasonal	Phase 3	Canada	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Rhinitis, Allergic, Seasonal	Phase 3	Denmark	Regeneron Pharmaceuticals, Inc.	14 Jan 2021
Rhinitis, Allergic, Seasonal	Phase 3	Germany	Regeneron Pharmaceuticals, Inc.	14 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04709575 (CTgov)	Phase 3	Rhinitis, Allergic, Seasonal \| Conjunctivitis	353	REGN5715+REGN5714+REGN5713 (REGN5713-5714-5715)	dfwhpfqoax(jwieelxkuh) = fiabzbjcsw yljewzhedb (qzowyzihzr, 0.6545) View more	-	27 Oct 2022
				Placebo (Placebo Only)	dfwhpfqoax(jwieelxkuh) = wwoccmwozt yljewzhedb (qzowyzihzr, 0.6534) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis